Email this article Patsient vysokogo kardiovaskulyarnogo riska: ot organoprotektsii k uluchsheniyu prognoza
- Authors: Skibitskiy VV1
-
Affiliations:
- Issue: Vol 8, No 4 (2011)
- Pages: 39-42
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33143
- DOI: https://doi.org/10.26442/SG33143
- ID: 33143
Cite item
Full Text
Abstract
References
- Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2005; 4 (1): 4-9.
- Диагностика и лечение артериальной гипертензии (рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-26.
- Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009; 27: 2121-58.
- Dahlot B, Devereux RD, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
- Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 14 (116): 700-5.
- Rayner BL. Effect of Losartan Versus Candesartan on Uric Acid, Renal Function, and Fibrinogen in Patients With Hypertension and Hyperuricemia Associated With Diuretics. Am J Hypertens 2006; 19: 208-13.
- Puig JG et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. Journal of Hypertension 1999; 17: 1033-9.
- Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66: 1714-5.
- Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
- Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-6.
- Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25: 4: 785-91.
- Hou FF, Xie D, Zhang X et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency. J Am Soc Nephrol 2007; 18: 1889-98.
- Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 6: 355: 9215: 1582-7.
- Konstam MA, Neaton JD, Dickstein K et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374 (9704): 1840-8.
- Špinar J, Vítovec J, Souček M et al. Сравнение рекомендованных доз блокаторов рецепторов ангиотензина и ингибиторов ангиотензин-превращающего фермента (исследование CORD). Кардиоваскулярная терапия и профилактика 2009; 8 (4): 63-70.
- Линчак Р.М., Шумилова К.М., Мартынюк А.Д. и др. Применение комбинированного препарата лозартана и гидрохлортиазида в антигипертензивной терапии. Рациональная фармакотерапия в кардиологии. 2006; 1: 11-8.
Supplementary files
